JUNS · Jupiter Neurosciences, Inc.
$0.12
-0.03 (-20.39%)
At close · Jul 24
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“In management's opinion, these conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of at least twelve months from the date of this report.”View the 10-Q filed May 14, 2026
Market Cap
$4.39M
Shares
36.28M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.15
Open$0.18
Day$0.14–0.18
52W$0.14–1.85
Avg vol 30d15.0M
Short int239K · 0.7% float · 1.0d
Short vol34%
DataDec 2024–Jul 2026
Filing10-Q · May 14
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−78%
below
Price vs 50-day avg
−35%
below
RSI (14)
32
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−40%
trailing
6-month return
−75%
trailing
YTD return
−85%
this year
Relative strength
−81%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.66% of float · ▼ -74.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 1-yr range
Squeeze score
27
low risk · 0–100
Fundamentals
Gross margin
81%
EPS growth
−213%
Y/Y
Quant / Vol
risk profile
Volatility
109%
annualized · 1-yr
Max drawdown
−92%
past year
ATR
19.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−78%
Bearish
Price vs 50-day avg
−35%
Bearish
RSI (14)
32
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-17% holders QoQ · +5 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.66% of float · ▼ -74.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
10 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $2
vs 200-day avg -78%
vs 50-day avg -35%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JUNS
this stock
Jupiter Neurosciences, Inc.
|
$4.39M | -85.0% | — | — | 0.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JUNS | -12.1% | -39.5% | -74.5% | -28.6% | -85.0% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -10.4% | -40.2% | -80.9% | -27.4% | -93.3% |